OR WAIT 15 SECS
The use of probiotics and xylitol chewing gum to alleviate sore throat symptoms -- as an alternative to antibiotics -- appears to have no effect, according to a randomized controlled trial (RCT) published in CMAJ (Canadian Medical Association Journal).
"Simple over-the-counter treatments could potentially limit the effects of both bacterial and viral infections and help patients to manage symptoms," says Dr. Paul Little of the Primary Care Group at the University of Southampton in Southampton, United Kingdom. "This would enable self-management, potentially facilitate a quicker return to normal activities, and reduce the pressure to use antibiotics."
Evidence exists that indicates probiotics and xylitol, a birch sugar that prevents bacterial growth, can help reduce recurrence of upper respiratory tract infections.
The study included 934 people in the UK during the four year study period (June 2010 to 2014), of whom 689 provided complete data for the trial. Using a symptom diary, participants reported the number of probiotic capsules and sticks of chewing gum used each day, as well as the severity of symptoms. They were compliant if they had taken 75 percent of their allotted treatment.
Researchers found no significant effect of either probiotics or xylitol on sore throat (pharyngitis) symptoms.
"There were no significant differences between groups for both the xylitol and the probiotic groups, which suggests that neither intervention helped in controlling acute symptoms," the authors write.
The study is one of only a few that looks at the effectiveness of two potentially useful alternative therapies for acute sore throats.
"There is no reason for clinicians to advise patients to use either of these treatments for the symptomatic management of pharyngitis," they conclude.
The study was conducted by researchers from the University of Southampton, Southampton, UK, with a patient collaborator.
"Probiotic capsules and xylitol chewing gum to manage symptoms of pharyngitis: a randomized controlled factorial trial" was published Dec. 18, 2017.
Source: Canadian Medical Association Journal